Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Transplantation Conditioning | 34 | 2022 | 1598 | 2.220 |
Why?
|
Graft vs Host Disease | 30 | 2023 | 2957 | 1.930 |
Why?
|
Hematopoietic Stem Cell Transplantation | 40 | 2023 | 5442 | 1.900 |
Why?
|
Cyclophosphamide | 22 | 2023 | 2242 | 1.820 |
Why?
|
Bone Marrow Transplantation | 28 | 2023 | 2765 | 1.820 |
Why?
|
Hematologic Neoplasms | 20 | 2019 | 1832 | 1.320 |
Why?
|
Bone Neoplasms | 9 | 2022 | 2529 | 1.140 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 9 | 2017 | 272 | 1.130 |
Why?
|
Chondrosarcoma | 4 | 2021 | 309 | 1.070 |
Why?
|
Tissue Donors | 12 | 2020 | 2240 | 1.050 |
Why?
|
Osteoblastoma | 2 | 2021 | 24 | 0.990 |
Why?
|
Osteoma, Osteoid | 2 | 2021 | 80 | 0.950 |
Why?
|
HLA Antigens | 12 | 2021 | 1381 | 0.680 |
Why?
|
Hematologic Diseases | 3 | 2023 | 498 | 0.660 |
Why?
|
Busulfan | 9 | 2021 | 263 | 0.660 |
Why?
|
Antigens, CD34 | 5 | 2017 | 657 | 0.630 |
Why?
|
Hematopoietic Stem Cell Mobilization | 7 | 2017 | 227 | 0.620 |
Why?
|
Cord Blood Stem Cell Transplantation | 4 | 2023 | 314 | 0.550 |
Why?
|
Immunosuppressive Agents | 13 | 2017 | 4149 | 0.540 |
Why?
|
Soft Tissue Neoplasms | 3 | 2021 | 1363 | 0.530 |
Why?
|
Hospitals, Special | 1 | 2015 | 101 | 0.510 |
Why?
|
Haplotypes | 6 | 2017 | 2779 | 0.480 |
Why?
|
Transplantation, Homologous | 24 | 2020 | 4776 | 0.460 |
Why?
|
Antilymphocyte Serum | 3 | 2021 | 492 | 0.460 |
Why?
|
Vidarabine | 8 | 2021 | 345 | 0.430 |
Why?
|
Histocompatibility Testing | 9 | 2017 | 741 | 0.390 |
Why?
|
Lymphocyte Depletion | 4 | 2012 | 608 | 0.370 |
Why?
|
Chondroma | 2 | 2021 | 58 | 0.360 |
Why?
|
Lipoma | 1 | 2012 | 334 | 0.360 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2012 | 380 | 0.360 |
Why?
|
Fever | 2 | 2014 | 1616 | 0.350 |
Why?
|
Vidarabine Phosphate | 4 | 2014 | 11 | 0.350 |
Why?
|
Fetal Blood | 4 | 2023 | 1318 | 0.350 |
Why?
|
Liposarcoma | 1 | 2012 | 333 | 0.340 |
Why?
|
Myeloablative Agonists | 6 | 2016 | 218 | 0.330 |
Why?
|
Tissue and Organ Harvesting | 4 | 2020 | 369 | 0.320 |
Why?
|
Guideline Adherence | 2 | 2015 | 2266 | 0.320 |
Why?
|
Histocompatibility | 4 | 2016 | 330 | 0.310 |
Why?
|
Bone Marrow | 6 | 2023 | 2948 | 0.290 |
Why?
|
Blood Component Removal | 2 | 2012 | 125 | 0.280 |
Why?
|
Donor Selection | 4 | 2019 | 201 | 0.270 |
Why?
|
Granulocyte Colony-Stimulating Factor | 5 | 2016 | 648 | 0.260 |
Why?
|
Leukemia, Myeloid, Acute | 6 | 2021 | 3523 | 0.250 |
Why?
|
Adult | 59 | 2022 | 214055 | 0.230 |
Why?
|
Adolescent | 40 | 2022 | 85781 | 0.230 |
Why?
|
Arthroplasty, Replacement, Ankle | 1 | 2022 | 26 | 0.220 |
Why?
|
Health Care Surveys | 1 | 2010 | 2453 | 0.210 |
Why?
|
Young Adult | 29 | 2021 | 56430 | 0.200 |
Why?
|
Humans | 95 | 2023 | 744343 | 0.200 |
Why?
|
Enchondromatosis | 1 | 2021 | 14 | 0.200 |
Why?
|
Gene Rearrangement | 3 | 2021 | 1179 | 0.200 |
Why?
|
T-Lymphocytes | 6 | 2017 | 10180 | 0.200 |
Why?
|
Middle Aged | 55 | 2022 | 213383 | 0.190 |
Why?
|
Aged | 43 | 2023 | 163280 | 0.190 |
Why?
|
Excitatory Amino Acid Agonists | 1 | 2001 | 146 | 0.190 |
Why?
|
Immunotherapy, Adoptive | 2 | 2022 | 1270 | 0.190 |
Why?
|
N-Methylaspartate | 1 | 2001 | 231 | 0.190 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2022 | 297 | 0.180 |
Why?
|
Transplantation Chimera | 4 | 2015 | 612 | 0.180 |
Why?
|
Erythroid Precursor Cells | 1 | 2001 | 218 | 0.180 |
Why?
|
Male | 64 | 2022 | 350118 | 0.180 |
Why?
|
Chondromatosis, Synovial | 1 | 2019 | 17 | 0.180 |
Why?
|
Receptors, Dopamine D1 | 1 | 2001 | 291 | 0.170 |
Why?
|
Pruritus | 1 | 2022 | 361 | 0.170 |
Why?
|
Disease-Free Survival | 11 | 2016 | 6895 | 0.170 |
Why?
|
Activin Receptors, Type II | 1 | 2019 | 127 | 0.160 |
Why?
|
Pyramidal Cells | 1 | 2001 | 363 | 0.160 |
Why?
|
Female | 60 | 2022 | 380194 | 0.160 |
Why?
|
Neurotoxicity Syndromes | 1 | 2022 | 290 | 0.150 |
Why?
|
Haploidy | 2 | 2016 | 136 | 0.150 |
Why?
|
Killer Cells, Natural | 2 | 2017 | 2133 | 0.150 |
Why?
|
Child | 24 | 2022 | 77709 | 0.150 |
Why?
|
Proto-Oncogene Proteins c-fos | 1 | 2019 | 575 | 0.150 |
Why?
|
Hematopoietic Stem Cells | 3 | 2017 | 3386 | 0.140 |
Why?
|
Giant Cell Tumor of Bone | 1 | 2017 | 116 | 0.140 |
Why?
|
Achilles Tendon | 1 | 2018 | 157 | 0.140 |
Why?
|
Tendinopathy | 1 | 2018 | 154 | 0.130 |
Why?
|
Retrospective Studies | 20 | 2022 | 77449 | 0.130 |
Why?
|
Radioimmunotherapy | 1 | 2015 | 91 | 0.130 |
Why?
|
Living Donors | 2 | 2010 | 620 | 0.130 |
Why?
|
Fibronectins | 1 | 2019 | 726 | 0.130 |
Why?
|
Hodgkin Disease | 3 | 2011 | 1415 | 0.130 |
Why?
|
Whole-Body Irradiation | 4 | 2021 | 449 | 0.130 |
Why?
|
Biopsy, Needle | 1 | 2020 | 1641 | 0.130 |
Why?
|
Erdheim-Chester Disease | 1 | 2014 | 11 | 0.130 |
Why?
|
Cell Separation | 1 | 2001 | 1751 | 0.130 |
Why?
|
Osteoarthritis | 1 | 2022 | 1036 | 0.130 |
Why?
|
Dyspnea | 1 | 2022 | 1303 | 0.120 |
Why?
|
Recurrence | 10 | 2014 | 8340 | 0.120 |
Why?
|
Biomarkers, Pharmacological | 2 | 2013 | 162 | 0.120 |
Why?
|
Radiography, Thoracic | 1 | 2020 | 1265 | 0.120 |
Why?
|
Melphalan | 1 | 2015 | 431 | 0.120 |
Why?
|
Lymphopoiesis | 1 | 2014 | 135 | 0.120 |
Why?
|
Isoantibodies | 1 | 2018 | 679 | 0.120 |
Why?
|
Graft Survival | 5 | 2015 | 3737 | 0.120 |
Why?
|
Central Nervous System Neoplasms | 1 | 2022 | 895 | 0.120 |
Why?
|
Bacteremia | 1 | 2020 | 962 | 0.110 |
Why?
|
Area Under Curve | 3 | 2013 | 1654 | 0.110 |
Why?
|
Filgrastim | 4 | 2015 | 133 | 0.110 |
Why?
|
Lymphoma | 1 | 2022 | 1877 | 0.110 |
Why?
|
Mesenchymal Stem Cell Transplantation | 1 | 2018 | 496 | 0.110 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2022 | 2540 | 0.110 |
Why?
|
Survival Rate | 8 | 2017 | 12788 | 0.110 |
Why?
|
Respiratory Insufficiency | 1 | 2021 | 1199 | 0.110 |
Why?
|
Accreditation | 1 | 2015 | 450 | 0.110 |
Why?
|
Foot Diseases | 1 | 2013 | 143 | 0.110 |
Why?
|
Point-of-Care Systems | 1 | 2001 | 1177 | 0.100 |
Why?
|
Treatment Outcome | 18 | 2022 | 63114 | 0.100 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2011 | 11524 | 0.100 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2019 | 2649 | 0.100 |
Why?
|
GTP Phosphohydrolases | 1 | 2014 | 509 | 0.100 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2023 | 9239 | 0.100 |
Why?
|
Bone Marrow Cells | 1 | 2019 | 2513 | 0.100 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2014 | 640 | 0.090 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2017 | 627 | 0.090 |
Why?
|
Synovitis, Pigmented Villonodular | 1 | 2010 | 34 | 0.090 |
Why?
|
Prefrontal Cortex | 1 | 2001 | 2147 | 0.090 |
Why?
|
Blood Donors | 1 | 2012 | 355 | 0.090 |
Why?
|
Graft Rejection | 5 | 2018 | 4397 | 0.090 |
Why?
|
Pain | 5 | 2022 | 4986 | 0.090 |
Why?
|
Osteitis | 1 | 2009 | 33 | 0.090 |
Why?
|
Foot | 1 | 2013 | 527 | 0.090 |
Why?
|
Fanconi Anemia | 1 | 2012 | 319 | 0.090 |
Why?
|
Salvage Therapy | 1 | 2016 | 1275 | 0.090 |
Why?
|
Incidence | 9 | 2023 | 20947 | 0.090 |
Why?
|
Lymphocyte Transfusion | 2 | 2016 | 236 | 0.080 |
Why?
|
Physician Executives | 1 | 2010 | 128 | 0.080 |
Why?
|
Sarcoma | 1 | 2020 | 1897 | 0.080 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 2011 | 1381 | 0.080 |
Why?
|
Hospital Bed Capacity | 1 | 2010 | 214 | 0.080 |
Why?
|
Pilot Projects | 4 | 2019 | 8324 | 0.080 |
Why?
|
Mixed Tumor, Malignant | 1 | 2008 | 15 | 0.080 |
Why?
|
Leukemia, Myeloid | 3 | 2014 | 707 | 0.080 |
Why?
|
Immunoconjugates | 1 | 2015 | 901 | 0.080 |
Why?
|
Liposarcoma, Myxoid | 1 | 2008 | 67 | 0.080 |
Why?
|
Gene Amplification | 1 | 2012 | 1063 | 0.080 |
Why?
|
Fetal Proteins | 1 | 2008 | 94 | 0.080 |
Why?
|
Myoepithelioma | 1 | 2008 | 43 | 0.080 |
Why?
|
Blood Specimen Collection | 1 | 2009 | 246 | 0.080 |
Why?
|
Killer Cells, Lymphokine-Activated | 1 | 2007 | 42 | 0.080 |
Why?
|
Follow-Up Studies | 7 | 2020 | 39050 | 0.080 |
Why?
|
Hemoglobinuria, Paroxysmal | 1 | 2008 | 102 | 0.070 |
Why?
|
Models, Biological | 3 | 2014 | 9583 | 0.070 |
Why?
|
Muscle Neoplasms | 1 | 2008 | 139 | 0.070 |
Why?
|
Histones | 1 | 2017 | 2599 | 0.070 |
Why?
|
Stem Cell Transplantation | 1 | 2016 | 1620 | 0.070 |
Why?
|
Child, Preschool | 10 | 2022 | 41006 | 0.070 |
Why?
|
Magnetic Resonance Imaging | 7 | 2022 | 35421 | 0.070 |
Why?
|
Kidney Failure, Chronic | 1 | 2019 | 2538 | 0.070 |
Why?
|
Social Class | 1 | 2015 | 1999 | 0.070 |
Why?
|
Chronic Disease | 6 | 2023 | 9146 | 0.070 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 1 | 2007 | 307 | 0.070 |
Why?
|
Joint Diseases | 1 | 2010 | 480 | 0.070 |
Why?
|
Muscle, Skeletal | 2 | 2013 | 4931 | 0.070 |
Why?
|
Combined Modality Therapy | 4 | 2012 | 8642 | 0.070 |
Why?
|
T-Box Domain Proteins | 1 | 2008 | 471 | 0.070 |
Why?
|
Bone Marrow Purging | 2 | 2002 | 109 | 0.060 |
Why?
|
Fatigue | 1 | 2012 | 1531 | 0.060 |
Why?
|
Myelodysplastic Syndromes | 3 | 2016 | 1352 | 0.060 |
Why?
|
Conflict of Interest | 1 | 2010 | 544 | 0.060 |
Why?
|
Hemangioma | 1 | 2010 | 738 | 0.060 |
Why?
|
Acute Disease | 5 | 2021 | 7149 | 0.060 |
Why?
|
Chordoma | 1 | 2008 | 359 | 0.060 |
Why?
|
Adoptive Transfer | 1 | 2007 | 844 | 0.060 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2008 | 903 | 0.060 |
Why?
|
Kidney Transplantation | 1 | 2019 | 4251 | 0.060 |
Why?
|
Immune Tolerance | 1 | 2012 | 2258 | 0.060 |
Why?
|
Informed Consent | 1 | 2010 | 995 | 0.060 |
Why?
|
Remission Induction | 4 | 2013 | 2386 | 0.060 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2017 | 2988 | 0.060 |
Why?
|
Blood Cell Count | 2 | 2015 | 403 | 0.060 |
Why?
|
Cell Count | 2 | 2019 | 1856 | 0.050 |
Why?
|
Transplantation, Autologous | 4 | 2018 | 2124 | 0.050 |
Why?
|
Family | 2 | 2011 | 3147 | 0.050 |
Why?
|
Aged, 80 and over | 5 | 2021 | 57776 | 0.050 |
Why?
|
United States | 5 | 2023 | 69872 | 0.050 |
Why?
|
Neoplasm, Residual | 2 | 2017 | 973 | 0.050 |
Why?
|
Hypoglycemia | 1 | 2009 | 861 | 0.050 |
Why?
|
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine | 1 | 2001 | 54 | 0.050 |
Why?
|
Knee Joint | 1 | 2010 | 1680 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 3 | 2017 | 6538 | 0.050 |
Why?
|
State Medicine | 1 | 2022 | 217 | 0.050 |
Why?
|
Arthrodesis | 1 | 2022 | 189 | 0.050 |
Why?
|
Fluorometry | 1 | 2001 | 106 | 0.050 |
Why?
|
Proportional Hazards Models | 2 | 2015 | 12354 | 0.050 |
Why?
|
Hematopoiesis | 2 | 2021 | 2072 | 0.050 |
Why?
|
Mutation | 4 | 2020 | 29786 | 0.050 |
Why?
|
Diagnosis, Differential | 4 | 2022 | 12959 | 0.050 |
Why?
|
Chimerism | 1 | 2021 | 158 | 0.050 |
Why?
|
Nuclear Family | 1 | 2002 | 318 | 0.050 |
Why?
|
Lymphoma, B-Cell | 1 | 2007 | 931 | 0.050 |
Why?
|
Tomography, X-Ray Computed | 3 | 2020 | 20129 | 0.050 |
Why?
|
Hyperglycemia | 1 | 2009 | 1373 | 0.040 |
Why?
|
Interleukin-2 | 1 | 2007 | 1904 | 0.040 |
Why?
|
Consensus | 2 | 2019 | 2959 | 0.040 |
Why?
|
Ankle | 1 | 2022 | 327 | 0.040 |
Why?
|
Switzerland | 1 | 2019 | 255 | 0.040 |
Why?
|
Antigens, CD19 | 1 | 2022 | 380 | 0.040 |
Why?
|
Oncogene Fusion | 1 | 2019 | 99 | 0.040 |
Why?
|
Mycophenolic Acid | 2 | 2013 | 343 | 0.040 |
Why?
|
Cyclic AMP-Dependent Protein Kinases | 1 | 2001 | 491 | 0.040 |
Why?
|
Ankle Joint | 1 | 2022 | 411 | 0.040 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2011 | 4386 | 0.040 |
Why?
|
Injections, Intravenous | 2 | 2011 | 1420 | 0.040 |
Why?
|
Patch-Clamp Techniques | 1 | 2001 | 964 | 0.040 |
Why?
|
Dopamine Agonists | 1 | 2001 | 355 | 0.040 |
Why?
|
England | 1 | 2019 | 522 | 0.040 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2019 | 188 | 0.040 |
Why?
|
Hyperplasia | 1 | 2021 | 1185 | 0.040 |
Why?
|
Ciprofloxacin | 1 | 2020 | 315 | 0.040 |
Why?
|
London | 1 | 2018 | 233 | 0.040 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2019 | 250 | 0.040 |
Why?
|
Recombinant Proteins | 3 | 2014 | 6622 | 0.040 |
Why?
|
Electrophysiology | 1 | 2001 | 1308 | 0.040 |
Why?
|
Immunohistochemistry | 3 | 2019 | 11366 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2011 | 4479 | 0.040 |
Why?
|
Postoperative Complications | 3 | 2019 | 15295 | 0.040 |
Why?
|
Arthralgia | 1 | 2022 | 456 | 0.040 |
Why?
|
Membrane Proteins | 1 | 2014 | 7880 | 0.040 |
Why?
|
Calcium Channels | 1 | 2001 | 622 | 0.040 |
Why?
|
Cost-Benefit Analysis | 2 | 2023 | 5391 | 0.030 |
Why?
|
Animals | 4 | 2022 | 168757 | 0.030 |
Why?
|
Antineoplastic Agents | 4 | 2012 | 13695 | 0.030 |
Why?
|
Receptors, KIR | 1 | 2016 | 113 | 0.030 |
Why?
|
Nitriles | 1 | 2021 | 956 | 0.030 |
Why?
|
Lung Neoplasms | 1 | 2020 | 13102 | 0.030 |
Why?
|
Receptors, Tumor Necrosis Factor, Type I | 1 | 2017 | 264 | 0.030 |
Why?
|
Cyclosporine | 1 | 1998 | 786 | 0.030 |
Why?
|
Time Factors | 5 | 2017 | 40075 | 0.030 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 1 | 2017 | 310 | 0.030 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2018 | 629 | 0.030 |
Why?
|
Survival Analysis | 4 | 2014 | 10252 | 0.030 |
Why?
|
Extremities | 1 | 2020 | 865 | 0.030 |
Why?
|
Blood Transfusion | 1 | 2001 | 1301 | 0.030 |
Why?
|
Drug Administration Schedule | 2 | 2017 | 4933 | 0.030 |
Why?
|
Antibiotic Prophylaxis | 1 | 2020 | 639 | 0.030 |
Why?
|
Cause of Death | 2 | 2021 | 3584 | 0.030 |
Why?
|
Spine | 1 | 2021 | 1144 | 0.030 |
Why?
|
Bayes Theorem | 2 | 2014 | 2309 | 0.030 |
Why?
|
Heel | 1 | 2013 | 36 | 0.030 |
Why?
|
Half-Life | 1 | 2014 | 661 | 0.030 |
Why?
|
United States Food and Drug Administration | 1 | 2021 | 1584 | 0.030 |
Why?
|
Injections, Subcutaneous | 1 | 2014 | 666 | 0.030 |
Why?
|
Disease Progression | 3 | 2017 | 13284 | 0.030 |
Why?
|
Anesthesia | 2 | 2015 | 1561 | 0.030 |
Why?
|
Convalescence | 1 | 2012 | 105 | 0.030 |
Why?
|
Lymphocyte Count | 1 | 2014 | 793 | 0.030 |
Why?
|
Decision Trees | 1 | 2014 | 506 | 0.030 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2017 | 871 | 0.030 |
Why?
|
Prospective Studies | 4 | 2019 | 53288 | 0.030 |
Why?
|
Risk Factors | 6 | 2014 | 72290 | 0.020 |
Why?
|
Lymphocytes | 1 | 2019 | 2617 | 0.020 |
Why?
|
Antigens, Surface | 1 | 2015 | 1663 | 0.020 |
Why?
|
Pyrazoles | 1 | 2021 | 1972 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2015 | 1880 | 0.020 |
Why?
|
Bone and Bones | 1 | 2021 | 2575 | 0.020 |
Why?
|
Antibodies, Monoclonal | 2 | 2015 | 9274 | 0.020 |
Why?
|
Transplantation Immunology | 1 | 2012 | 546 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2001 | 5974 | 0.020 |
Why?
|
Histocytochemistry | 1 | 2011 | 719 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2019 | 15076 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 1 | 2001 | 8301 | 0.020 |
Why?
|
Siblings | 1 | 2014 | 854 | 0.020 |
Why?
|
Syncope | 1 | 2012 | 429 | 0.020 |
Why?
|
Pyrimidines | 1 | 2021 | 2942 | 0.020 |
Why?
|
Europe | 1 | 2015 | 3339 | 0.020 |
Why?
|
Comparative Effectiveness Research | 1 | 2014 | 681 | 0.020 |
Why?
|
Cytomegalovirus Infections | 1 | 2015 | 820 | 0.020 |
Why?
|
Glutathione Transferase | 1 | 2010 | 595 | 0.020 |
Why?
|
Prognosis | 4 | 2017 | 29063 | 0.020 |
Why?
|
Myeloproliferative Disorders | 1 | 2014 | 606 | 0.020 |
Why?
|
Spermatogonia | 1 | 2008 | 29 | 0.020 |
Why?
|
Gene Expression | 2 | 2014 | 7799 | 0.020 |
Why?
|
International Cooperation | 1 | 2014 | 1420 | 0.020 |
Why?
|
Exanthema | 1 | 2012 | 501 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2017 | 6171 | 0.020 |
Why?
|
Quality of Life | 2 | 2023 | 12804 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2017 | 19905 | 0.020 |
Why?
|
Reoperation | 1 | 2017 | 4201 | 0.020 |
Why?
|
Hemangioblastoma | 1 | 2008 | 70 | 0.020 |
Why?
|
Leukocytes, Mononuclear | 1 | 2014 | 1836 | 0.020 |
Why?
|
Blood Component Transfusion | 1 | 2008 | 143 | 0.020 |
Why?
|
Infant | 3 | 2010 | 35136 | 0.020 |
Why?
|
Synovial Membrane | 1 | 2010 | 507 | 0.020 |
Why?
|
Leukemia | 1 | 2015 | 1511 | 0.020 |
Why?
|
Nonlinear Dynamics | 1 | 2010 | 502 | 0.020 |
Why?
|
Leukapheresis | 1 | 2007 | 131 | 0.020 |
Why?
|
Body Mass Index | 2 | 2015 | 12720 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2016 | 15540 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2017 | 5078 | 0.020 |
Why?
|
Cell Lineage | 1 | 2015 | 2504 | 0.020 |
Why?
|
Neoplasms | 2 | 2014 | 21683 | 0.020 |
Why?
|
Body Weight | 1 | 2017 | 4669 | 0.020 |
Why?
|
Income | 1 | 2015 | 1913 | 0.020 |
Why?
|
Algorithms | 2 | 2011 | 13881 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2020 | 11031 | 0.020 |
Why?
|
Multiple Myeloma | 1 | 2003 | 5181 | 0.020 |
Why?
|
Medicare | 1 | 2023 | 6566 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2010 | 2274 | 0.020 |
Why?
|
Diphosphonates | 1 | 2009 | 623 | 0.020 |
Why?
|
Rats | 1 | 2001 | 24260 | 0.020 |
Why?
|
Lymphoma, Mantle-Cell | 1 | 2007 | 233 | 0.020 |
Why?
|
Tacrolimus | 1 | 2008 | 743 | 0.020 |
Why?
|
Virus Activation | 1 | 2006 | 319 | 0.020 |
Why?
|
Chromatography, Liquid | 1 | 2008 | 976 | 0.010 |
Why?
|
Immunotherapy | 1 | 2000 | 4445 | 0.010 |
Why?
|
Gastrointestinal Diseases | 1 | 2012 | 1170 | 0.010 |
Why?
|
Receptors, IgG | 1 | 2007 | 582 | 0.010 |
Why?
|
Drug Monitoring | 1 | 2010 | 956 | 0.010 |
Why?
|
Proteomics | 1 | 2017 | 3638 | 0.010 |
Why?
|
Sex Factors | 1 | 2017 | 10397 | 0.010 |
Why?
|
Ambulatory Care Facilities | 1 | 2010 | 933 | 0.010 |
Why?
|
Risk | 1 | 2016 | 9687 | 0.010 |
Why?
|
Cohort Studies | 3 | 2014 | 40561 | 0.010 |
Why?
|
Administration, Oral | 1 | 2010 | 3913 | 0.010 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2008 | 501 | 0.010 |
Why?
|
Multivariate Analysis | 2 | 2010 | 12245 | 0.010 |
Why?
|
Amino Acid Substitution | 1 | 2007 | 1791 | 0.010 |
Why?
|
Lung | 1 | 2020 | 9856 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2020 | 7181 | 0.010 |
Why?
|
Testicular Neoplasms | 1 | 2008 | 804 | 0.010 |
Why?
|
Postoperative Care | 1 | 2008 | 1486 | 0.010 |
Why?
|
Baltimore | 1 | 2001 | 231 | 0.010 |
Why?
|
Health Expenditures | 1 | 2014 | 2348 | 0.010 |
Why?
|
Herpesvirus 4, Human | 1 | 2006 | 1041 | 0.010 |
Why?
|
Mass Spectrometry | 1 | 2008 | 2203 | 0.010 |
Why?
|
Health Care Costs | 1 | 2014 | 3209 | 0.010 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2006 | 570 | 0.010 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2009 | 2282 | 0.010 |
Why?
|
Leukocyte Count | 1 | 2002 | 1588 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2014 | 9959 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2015 | 18029 | 0.010 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2000 | 693 | 0.010 |
Why?
|
Antigens, CD | 1 | 2007 | 4026 | 0.010 |
Why?
|
Computer Simulation | 1 | 2010 | 6196 | 0.010 |
Why?
|
Genotype | 1 | 2010 | 12951 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2006 | 6489 | 0.010 |
Why?
|
Blood Glucose | 1 | 2009 | 6256 | 0.010 |
Why?
|
Hospitalization | 1 | 2012 | 10262 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2010 | 12072 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2008 | 6234 | 0.010 |
Why?
|
Comorbidity | 1 | 2006 | 10388 | 0.010 |
Why?
|
Phenotype | 1 | 2008 | 16365 | 0.010 |
Why?
|
Obesity | 1 | 2012 | 12745 | 0.010 |
Why?
|
Neutrophils | 1 | 2002 | 3719 | 0.010 |
Why?
|
Mice | 1 | 2015 | 81183 | 0.010 |
Why?
|
Age Factors | 1 | 2003 | 18370 | 0.000 |
Why?
|
Longitudinal Studies | 1 | 2001 | 13989 | 0.000 |
Why?
|